ATLASBicara Therapeutics (BCAX) earnings date: Nov 9, 2026
Bicara Therapeutics (BCAX) reports earnings for the quarter ended Sep 30, 2026 on Mon, Nov 9, 2026. Analysts expect EPS of -$0.84.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on BCAX
| Last price | $8.69 (-4.8%) |
|---|---|
| Normal 1-day range (±1σ) | ±10.3% |
| Earnings beat history | Beat the EPS estimate in 1 of the last 3 reports |
These figures come from the same calibrated model and valuation as the Bicara Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Bicara Therapeutics reports on Nov 9, 2026. One email the day before, with ATLAS’s read on Bicara Therapeutics. You can switch it off at any time.
Alert me before BCAX reportsFree to start. Creating an account takes under a minute.
BCAX earnings at a glance
| Next report (confirmed) | Mon, Nov 9, 2026 |
|---|---|
| Time | Not stated |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.84 |
| Last report | Aug 11, 2026 · In line |
| Beat rate (last 3 reports) | 1 of 3 (33%) |
| Average EPS surprise | -5.6% |
| Average move around a report | ±4.8% (last 3) |
| Sector | Healthcare · Biotechnology |
Bicara Therapeutics earnings history: last 3 reports
Bicara Therapeutics last reported on Aug 11, 2026: EPS of -$0.82 against an estimate of -$0.83 (+1.2% surprise), in line with the estimate.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 11, 2026 | -$0.83 | -$0.82 | +1.2% | In line | -11.2% |
| Jul 8, 2026 | $0.04 | $0.05 | +25.0% | Beat | -2.4% |
| May 11, 2026 | -$0.65 | -$0.93 | -43.1% | Miss | -0.9% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for BCAX
See the fair value, the probability range and the earnings history of Bicara Therapeutics on its ATLAS page.
Bicara Therapeutics (BCAX) stock analysisPlans from €3.99 a month.
Bicara Therapeutics earnings: frequently asked questions
When does Bicara Therapeutics (BCAX) report earnings?
Bicara Therapeutics is scheduled to report on Monday, November 9, 2026 (the time of day has not been stated). ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for BCAX?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.84 per share (USD). Estimates can change before the report.
How often does BCAX beat earnings estimates?
Of its last 3 reports with a recorded result, Bicara Therapeutics beat the EPS estimate 1 times; the average surprise was -5.6%. Past results do not predict the next one.
How much does BCAX move around earnings?
Over its last 3 reports the stock moved an average of 4.8% (absolute, from the close before the report day to the close after it), and finished higher 0 of 3 times.
Did Bicara Therapeutics beat earnings estimates last quarter?
Bicara Therapeutics last reported on Aug 11, 2026: EPS of -$0.82 against an estimate of -$0.83 (+1.2% surprise), in line with the estimate.
How much does BCAX usually move in a day?
On a normal trading day the ATLAS model puts BCAX’s one-day range at about ±10.3%, with a 47% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Mon, Nov 9, 2026
Educational information, not investment advice. Disclaimer